MENLO PARK, Calif. – Octave Bioscience, a developer of a fully integrated care management solution that delivers insights for patients with neurodegenerative diseases, has completed its Series A funding of $14 million. The company previously raised $2.5 million in seed funding.
The funding will allow Octave Bioscience to complete development of its a digital health platform and begin to evaluate its impact in its initial disease state, multiple sclerosis.
“Multiple sclerosis is a high-cost disease that is highly variable,” said Dr. Thomas Hawes, an Octave Bioscience board member, in a statement. “Octave’s care management solution promises to transform neurodegenerative diseases by providing expanded insights into a patient’s specific disease stage, severity and progression, while accessing practice protocols and evidence-based care insights to improve patient outcomes and quality of life.”
Octave Bioscience’s care management solution was designed to start with a measurement system that includes assessing a patient’s biology through select biomarkers tied to inflammatory disease activity and neurodegeneration. It continuously tracks patient symptoms and disease trajectory using sensors and mobile tools.
Octave Bioscience also recently announced the appointments of two new board members: George Scangos, CEO of Vir Biotechnology; and Dr. Michael Pellini, managing partner at Section 32.